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INTRODUCTION
Endometrial cancer is the most common gynecologic malig­
nancy in women in the United States [1]. In 2009, an estimated 
42,160 new cases and 7,780 cancer­related deaths were anti­
cipated [1]. Certain clinical/pathologic characteristics have 
been shown to be significant predictors of outcome such as 
tumor grade. The 5­year survival rate for women with stage 
IA grade 1 cancer exceeds 90%, whereas it is only 69% for 
women with stage IA grade 3 cancer [2]. In addition to grade, 
the histopathological types of the endometrial cancer influence 
the outcome. For example, patients with uterine papillary 
serous carcinomas (UPSC) or carcinosarcomas that was term­
ed malignant mixed mullerian tumor are thought to have a 
worse outcome than those with endometrioid adenocarcino­
mas of the uterus. The poor outcome in these patients is 
often attributed to the more advanced stage at the time of 
diagnosis and disease relapse in the upper abdomen [3,4].
What is unclear from the literature is which one is worse 
between carcinosarcomas and UPSC. This is partly because 
of the low incidence of these tumors. To the best of our 
knowledge, there is no report which has compared the two 
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Objective: It is clear that uterine carcinosarcomas and uterine papillary serous carcinomas (UPSC) have an adverse impact on 
outcome, but whether carcinosarcomas are worse than UPSC is unclear. The purpose of this study is to compare the pathology, 
survival, and disease recurrence of patients with carcinosarcomas to patients with UPSC.
Methods: The medical records of patients diagnosed with carcinosarcomas and UPSC between 1996 and 2009 at Samsung 
Medical Center were retrospectively analyzed. Information from pathology reports, site of relapse, time to recurrence, and death 
was obtained. The survival analysis was performed using the Kaplan­Meier method.
Results: Thirty seven patients with carcinosarcomas and 38 patients with UPSC were identified during the study period. There 
was no significant difference in clinical characteristics including age, body mass index, proportion with advanced stage disease, 
rate of optimal debulking, and adjuvant treatment used. In addition, the pathology showed no significant difference in tumor 
size, myometrial involvement, lymphovascular invasion, peritoneal cytology, cervical invasion, and lymph node involvement. 
Patients with carcinosarcomas had similar patterns of relapse as the patients with UPSC. There was no difference in the progression­
free and overall survival between the carcinosarcomas and UPSC patients (p=0.804 and p=0.651, respectively).
Conclusion: Patients with carcinosarcomas had similar clinicopathological features compared to the patients with UPSC.
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tumors directly. This study was undertaken to compare the 
pathology, survival, and disease recurrence of patients with 
carcinosarcomas to patients with UPSC. 
MATERIALS AND METHODS
The study population included patients with primary uterine 
carcinosarcomas and UPSC treated at the Samsung Medical 
Center (SMC, Korea) between April 1996 and March 2009. 
Patients that were referred to our center for recurrent disease 
that developed following primary treatment at another ho­
spital, or those that had incomplete medical records were ex­
cluded from the analysis. In addition, mixed form carcinomas, 
regardless of the percent of carcinosarcomas or papillary se­
rous component, were excluded from this study. Data were 
retrieved from the patient’s records and death certificates. 
All pathology specimens were reassessed independently for 
their histopathological type, composition, and tumor cha  rac­
teristics, by two pathologists specializing in gynecology. Cases 
in which the diagnosis was not of the same opinion were 
also excluded from this series. All surgical and pathologic 
data, including histology, size, location, uterine variables, 
lymph node involvement (by areas: pelvic, para­aortic), and 
other organ involvement (peritoneum, omentum, bowel, 
diaphragm, spleen, liver), as well as cytology, were reviewed. 
Stage assignment was made according to the International 
Federation of Gynecology and Obstetrics (FIGO) surgical 
staging criteria reported in 1988 [5]. Information regarding 
treatment, including surgery, chemotherapy and/or radiation 
therapy and follow­up was collected. 
The patients were considered to be appropriately surgically 
staged if a lymphadenectomy was performed in patients with 
disease stages I through III. In patients with demonstrable intra­ 
abdominal or distant metastasis (stage IV disease), a biopsy 
of the extra­pelvic disease site was considered sufficient for 
surgical staging. The amount of residual disease after sur  gery, as 
abstracted from the surgical report, was recorded as optimal 
or suboptimal debulking. Optimal debulking was considered 
if all of the cancer had been removed with the exception of 
residual nodules that measured no more than 1 cm in the 
maximum diameter. 
Determination of patient outcomes, including the sites 
and number of treatment failures as well as the causes of 
death, were the primary study objectives. The specific sites 
of failure were categorized as local or distant. The dominant 
histological feature of disease recurrence was identified when 
available. A vaginal recurrence (out of local) was defined 
when the disease was diagnosed during follow­up at the 
proximal vaginal site. Treatment failures detected in the 
central pelvis, pelvic side wall, pelvic and/or para­aortic lymph 
nodes were considered local recurrences. Distant recurrences 
were defined as disease recurring in the upper abdomen or 
in extra­abdominal sites after initial treatment. Recurrences 
lacking pathological documentation were determined based 
on patient symptoms, imaging studies, elevated CA 125 levels 
and/or autopsy information. 
The progression­free survival (PFS) was defined as the time 
(months) from surgery to the date of the last follow­up or 
recurrence, and was based on imaging and tumor marker 
elevation. The overall survival (OS) was calculated from the 
day of surgery to the date of death or last contact. The PFS 
and OS were estimated on the basis of Kaplan­Meier curves. 
The statistical analysis was performed with SPSS ver. 12.0 (SPSS 
Inc., Chicago, IL, USA). A p­value less than 0.05 was considered 
statistically significant.
RESULTS
During the study period, 37 patients with carcinosarcomas 
and 38 patients with UPSC met the inclusion criteria. The 
Table 1. Clinical characteristics
Carcinosarcomas
(n=37)
UPSC
(n=38)
p-value
Age (yr)    57.7±11.6 59.1±7.6 0.523
BMI 24.6±3.9 25.0±3.3 0.633
Stage  0.819
    I-II 19 (51.4) 18 (47.4)
    III-IV 18 (48.6) 20 (52.6)
Debulking  0.720
    Optimal 30 (81.1) 32 (84.2)
    Suboptimal   7 (18.9)   6 (15.8)
LN dissection 0.335
    Pelvic only 15 (40.5) 17 (44.7)
    Pelvic+para-aortic 19 (51.4) 20 (52.6)
    Not done 3 (8.1) 1 (2.6)
Adjuvant therapy 0.349
    No adjuvant   7 (18.9) 2 (5.3)
    RTx only 14 (37.8) 17 (44.7)
    CTx only 11 (29.8) 14 (36.8)
    RTx+CTx   5 (13.5)   5 (13.2)
Values are presented as mean±SD or number (%). Student’s t-test, 
chi-square test, and fisher’s exact test were used.
UPSC, uterine papillary serous carcinomas; BMI, body mass index; LN, 
lymph node; RTx, radiotherapy; CTx, chemotherapy.Uterine papillary serous carcinomas vs. carcinosarcomas
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clinical characteristics of the study population are listed in 
Table 1. The mean age of carcinosarcomas group was 57.7 (±
11.6 years) and that of UPSC was 59.1 (±7.6 years). There was 
no difference in age and body mass index (BMI) (p=0.523 and 
p=0.633, respectively). The distribution of advanced stage 
disease (III and IV) was 48.6% and 52.6% for carcinosarcomas 
and UPSC, respectively. The rate of optimal debulking was 
81.1% and 84.2% for carcinosarcomas and UPSC, respectively. 
Most patients in both groups underwent comprehensive 
surgical staging, defined as peritoneal cytology and pelvic 
and/or para­aortic lymph node dissection; 91.9% of the 
carcinosarcomas, and 97.4 % of the UPSC. There was no 
statistical difference in the proportion of advanced stage 
disease, cases with optimal debulking and lymph node 
dissection between the two groups (p=0.819, p=0.720, and 
p=0.335, respectively). Furthermore, adjuvant therapy after 
primary surgery did not significantly differ between the two 
groups (p=0.349). 
Table 2 shows the pathological characteristics. There was 
no difference in the tumor size in the uterus, myometrial 
involvement, lymphovascular invasion, peritoneal cytology, 
cervical invasion, and lymph node involvement between the 
two groups (p=0.103, p=0.734, p=0.416, p=0.358, p=0.170, 
and p=0.449, respectively). 
Among the 75 patients, 28 (37.3%) had a recurrence; 15 
in the carcinosarcomas and 13 in the UPSC group (Table 3). 
The sites of recurrence included the vagina in 3 (4.0%), pelvis 
in 13 (17.3%), and more distant sites in 12 patients (16.0%). 
Eight of the 28 patients with a recurrence had more than one 
site of relapse. Sixteen patients (21.3%) had an isolated local 
recurrence. The most common site for distant recurrence 
was the lungs (5 of 12 patients) followed by intra­abdominal 
dissemination (4 of 12 patients), the liver, and the bones. In 
the four patients with intra­abdominal dissemination, two had 
carcinosarcomas and two had UPSC. There was no significant 
difference between the two groups with regard to local 
Table 2. Pathological characteristics
Carcinosarcomas
(n=37)
UPSC
(n=38) p-value
Tumor size in the uterus (cm) 0.103
    ≤2  5 (13.5) 11 (28.9)
    >2 32 (86.5) 27 (71.1)
Myometrial involvement (%) 0.734
    <50 or absent 19 (51.4) 21 (55.3)
    >50 18 (48.6) 17 (44.7)
Lymphovascular invasion 0.416
    Negative 21 (56.8) 18 (47.4)
    Positive 16 (43.2) 20 (52.6)
Peritoneal cytology* 0.358
    Negative 24 (85.7) 25 (75.8)
    Positive  4 (14.3)  8 (24.2)
Cervical invasion 0.170
    Negative 27 (73.0) 22 (57.9)
    Positive 10 (27.0) 16 (42.1)
Lymph node involvement* 0.449
    Negative 21 (61.8) 26 (70.3)
    Positive 13 (38.2) 11 (29.7)
Values are presented as number (%). Chi-square test and fisher’s 
exact test were used.
UPSC, uterine papillary serous carcinomas.
*Among the available data.
Table 3. Sites of recurrence
Carcinosarcomas 
(n=15/37)
UPSC 
(n=13/38)
All  
(n=28/75)
p-value
Local recurrence 9 (60) 7 (54) 16 (57) 0.807
    Vagina 2 1   3
    Pelvis 7 6 13
Distant recurrence* 6 (40) 6 (46) 12 (43)
    Intra-abdominal dissemination 2 2   4 
    Lung 3 2   5
    Liver 2 1   3
    Bone 1 1   2
    Brain 1 1   2
Values are presented as number (%). Chi-square test was used.
UPSC, uterine papillary serous carcinomas.
*Subclass was permitted counting with plural sites of recurrence.Taejong Song, et al.
DOI:10.3802/jgo.2011.22.2.83 86 www.ejgo.org
relapse; 60.0% (9 of 15) in the carcinosarcomas group; 54 % (7 
of 13) in the UPSC group (p=0.807). 
Fig. 1 shows the PFS and OS in patients for all disease 
stages. In patients with carcinosarcomas and UPSC, the five­
year PFS was 42.5% and 50.7%, respectively; there was no 
significant difference between carcinosarcomas and UPSC 
(p=0.804). The results were similar for both early stage (stage 
I and II; p=0.774) and advanced stage tumors (stage III and 
IV; p=0.918). In patients with carcinosarcomas and UPSC, the 
five­year OS was 61.0% and 66.8%, respectively; there was no 
significant difference between the two groups (p=0.651).
DISCUSSION
Given that carcinosarcomas and UPSC are rare uterine 
neoplasms, comparative studies of their clinical behavior 
and outcomes are limited. Generally, patients with 
carcinosarcomas are thought to have a poorer outcome 
than patients with high­risk endometrial carcinomas such 
as UPSC [6­8]; this is because of the traditional classification 
that carcinosarcomas had been regarded as a subtype of 
uterine sarcoma. However, in this study comparing UPSC 
with carcinosarcomas, the findings showed that patients 
with UPSC had a similar outcome compared to patients with 
carcinosarcomas. Considering the rarity of these tumors, 
our study is meaningful and it may contribute to better 
understanding of the behavior of these tumors.
However, there are some differences between the results 
of this study and prior studies. The major reason is that the 
current study is a direct comparison of carcinosarcomas 
versus UPSC alone for clinicopathologic outcomes. Amant 
et al. compared carcinosarcomas with non­endometrioid 
carcinomas in their study [6]. UPSC and clear cell carcinomas 
were included in the non­endometrioid carcinomas. The 
results showed that patients with carcinosarcomas had a 
poorer outcome when compared to patients with non­
endometrioid carcinomas. According to the FIGO sixth 
annual report on the results of treatment for gynecological 
cancer [9], however, patients with UPSC had a less favorable 
survival outcome than patients with clear cell carcinomas. The 
5­year survival rate was 52.6% for UPSC, compared to 62.5% 
for clear cell carcinomas. When only patients with stage I 
disease were analyzed, the 5­year survival rate was 79.9% for 
UPSC, compared to 85.1% for clear cell carcinomas. Such a 
comparison including the clear cell carcinomas in the UPSC 
group may magnify the differences between carcinosarcomas 
and UPSC. Vaidya et al. classified carcinosarcomas as cases and 
patients with high­risk endometrial carcinomas as controls [8]. 
Grade 3 endometrioid adenocarcinomas, clear cell carcinomas, 
and UPSC were included in the high­risk endometrial 
carcinomas. As a result, patients with carcinosarcomas had 
a poorer prognosis than patients with high­risk endometrial 
carcinomas. The difference between the groups was 
magnified due to the grade 3 endometrioid adenocarcinomas 
that were included in the cases; these tumors have been 
reported to have an adverse impact on outcomes with UPSC 
or carcinosarcomas in the literature [6,7,10].
Of interest were the similarities in the pattern of recurrence 
between the common epithelial endometrial carcinomas and 
the carcinosarcomas/UPSC. In a 1984 report on 379 patients 
with recurrent endometrial cancer at the Norwegian Radium 
Hospital, from 1960 to 1976 [11], the sites of recurrence 
were local in 190 patients (50.1%) and distant in 189 patients 
(49.9%). Although the site of recurrence has not been reported 
for carcinosarcomas, for UPSC it was local in six patients 
Fig. 1. Progression-free survival for all stages (A) and overall survival for all stages (B). UPSC, uterine papillary serous carcinomas.Uterine papillary serous carcinomas vs. carcinosarcomas
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(46%) and distant in seven patients (54%) according to a 
study reported by Alektiar et al. [12]. The data from this study 
showed that the carcinosarcomas was local in nine patients 
(60%) and distant in six patients (40%), and that the UPSC 
was local in seven patients (54%) and distant in six patients 
(46%). The sites of distant recurrence were similar for both 
study groups. The common sites of distant recurrence are the 
lungs and abdomen in the common epithelial endometrial 
carcinomas [13]. According to Amant et al. [6] and Alektiar et 
al. [12], the most common site in both groups is the lungs; this 
is consistent with the results of this study.
The findings of this study raise the question of why the patients 
with carcinosarcomas, traditionally regarded as a subtype of 
uterine sarcoma, had similar outcomes to the patients with 
UPSC. Recent research suggests that carcinosarcomas are 
mo  no  clonal in origin, with the sarcomatous component re­
pre  senting dedifferentiation of the carcinomatous portion [14]. 
However, the carcinomatous origins are thought to be the 
pri  mary characteristic. Histologically, tumor emboli within 
lym  pho  vascular channels and metastases primarily consist of 
carcinomatous components [15]. Further evidence that car  ci­
no  sarcomas develops from a single stem cell comes from stu­
dies examining the immunohistochemical expression of the 
p53 protein. The p53 protein expression was found in both 
the carcinomatous and sarcomatous portions of the tu  mor [16, 
17]. Carcinosarcomas has similar risk factors as endometrial 
car  cinomas. Both neoplasms are associated with obe  sity, nulli­
parity, and exogenous estrogen use [18]. Therefore, car  ci  no­
sar  comas are now classified as carcinomas rather than a mix  ture of 
carcinoma and sarcoma [19]. In addi  tion, the epidemiology, risk 
factors, and clinical behavior asso  cia  ted with carcinosarcomas 
suggest a closer relationship to endometrial carcinomas than 
to sarcoma. 
The limitations of this study include the following. The study 
was retrospective with inherent associated biases. Over the 
14 years of the study, the treatment protocols have changed. 
Furthermore, most prior studies on endometrial cancer have 
been performed on the Caucasian population [20,21]. The 
results of this study may be specific only to Asians; the survival 
differences associated with histopathological types vary 
considerably with racial background according to the study 
reported by Sherman and Devesa [22]. In addition, the number 
of patients was relatively small, which may have affected the 
results. Not all patients in this series underwent pelvic and 
para­aortic lymph node dissection, although most patients 
underwent pelvic dissection (91.9% in carcinosarcomas and 
97.3% in UPSC); therefore, the data from this study may not 
be applicable to patients that undergo routine dissection of 
pelvic and para­aortic lymph nodes.
In conclusion, the pathological features, strategies for 
adjuvant management, disease recurrence and death, 
as well as sites of relapse were similar in patients with 
carcinosarcomas and UPSC. Additional follow­up on a larger 
number of patients is needed to confirm the data from this 
study and expand our knowledge on these two malignancies.
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